Lito Sousa Seeks Experimental Drugs After Creutzfeldt‑Jakob Diagnosis as Trials and Firms Limit Access

Overview

• Lito Sousa, a Brazilian influencer, confirmed his Creutzfeldt‑Jakob disease diagnosis in a video recorded the day he learned the result and has since been receiving home and hospital care while preserving privacy and rest.
• The family shifted from trying to enroll him in active trials to requesting compassionate use of investigational drugs after formal enrollment requests were blocked or closed.
• Brazil’s Ministry of Health and Itamaraty have contacted U.S. trial teams and mobilized embassies, and the PRiSM study at the Broad Institute placed Lito on triage or screening but only as a control‑arm candidate requiring relocation and without guarantee of the experimental drug.
• Ionis Pharmaceuticals told the family that its ION717 study is in an early phase, is not accepting new participants, and is not available for expanded or compassionate access at this time.
• Doctors and family stress that Creutzfeldt‑Jakob is a rare, rapidly fatal prion disease with no approved cure, that current experimental approaches are preliminary and tightly regulated, and that the immediate human impact is a fast race to secure any possible option while managing care and protecting Lito’s remaining cognition.